Tech
ImmunityBio (IBRX) Stock Surges 12% Following Bullish Hedge Fund Analysis
ImmunityBio shares surged over 12% following a bullish analysis from the GA-Courtenay Special Situations Fund, highlighting Anktiva's manufacturing capacity and major revenue potential.